ArticleJournal of the American Heart Association2025
Use and Outcomes of the Medical Hybrid Procedure For Stage 1 Palliation in Infants With Hypoplastic Left Heart Syndrome and Variants.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Status of Patent Ductus Arteriosus Stenting: An International Practice Based Study.Pediatric cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundStaged palliation of hypoplastic left heart syndrome and variants begins with the Norwood or hybrid procedure. Hybrid palliation is used in a minority of cases and often reserved for high-risk patients. Stented hybrid (SH) comprises bilateral pulmonary artery bands and ductal stenting, and medical hybrid (MH) comprises bilateral pulmonary artery bands and prostaglandins. MH use and outcomes have not been well described. We sought to compare MH, SH, and surgical stage 1 (SS1) using a national database.
methodsPatients from the National Pediatric Cardiology Quality Improvement Collaborative database born between 2016 and 2021 were categorized by initial intervention: MH, SH, or SS1. Statistical comparisons and Kaplan-Meier analysis were performed.
resultsThis study included 2423 patients from 65 centers: 277 (11%) MH, 133 (5%) SH, and 2013 (83%) SS1. MH had lowest birth weight and gestational age, most noncardiac anomalies, and most preoperative risk factors. Most centers had minority MH, though use ranged from 0% to 82% at centers with ≥10 patients. Transplant-free 1-year survival was MH 56%, SH 66%, and SS1 81% (
conclusionsSurvival after MH is similar to SH and worse than SS1. This may be due to patient risk factors not controlled for in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.